• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
DXB
Click for more information
2.99% 32.5¢

DIMERIX LIMITED - Announcements

Market Cap $211.6M  ! watchlist Created with Sketch. Add to my watchlist

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The... Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
DXB Appendix 3B15/03/19
DXB Trial Update Presentation05/03/19
DXB Half Year Report & DMX-200 Clinical Trials Update26/02/19
DXB Half Yearly Report and AccountsPRICE SENSITIVE26/02/19
DXB Appendix 4C and Quarterly HighlightsPRICE SENSITIVE31/01/19
DXB Appendix 3B29/01/19
DXB Appendix 3B14/01/19
DXB Dimerix Receives R&D Tax Cash Rebate Totalling $1.07mPRICE SENSITIVE20/12/18
DXB Change of Director's Interest Notice27/11/18
DXB Appendix 3B27/11/18
DXB Dimerix Awarded $50,000 Innovation Connections Grant26/11/18
DXB 1st Patient Dosed in DMX-200 Clinical Trial for FSGSPRICE SENSITIVE22/11/18
DXB DXB Receives Orphan Drug Designation in EUPRICE SENSITIVE21/11/18
DXB FIRST PATIENT DOSED IN DMX-200 CLINICAL TRIALPRICE SENSITIVE19/11/18
DXB Change of Address12/11/18
DXB Results of Meeting30/10/18
DXB AGM Presentation and CEO Address30/10/18
DXB Appendix 4C - quarterlyPRICE SENSITIVE29/10/18
DXB AGM Dial-In Details25/10/18
DXB Investor Update15/10/18
DXB Appendix 3B24/09/18
DXB Notice of Annual General Meeting/Proxy Form21/09/18
DXB Change of Director's Interest Notice11/09/18
DXB Annual Report to shareholders30/08/18
DXB Appendix 4G and Corporate Governance Statement30/08/18
DXB Preliminary Final ReportPRICE SENSITIVE30/08/18
DXB Initial Director's Interest Notice28/08/18
DXB EXECUTIVE TEAM BOLSTERED THROUGH CEO & MD APPOINTMENTPRICE SENSITIVE27/08/18
DXB Quarterly Review & Appendix 4CPRICE SENSITIVE31/07/18
DXB Company Presentation27/07/18
DXB Change of Director Interest Notices x 224/07/18
DXB Ethics Approval Received Appendix 3B and S.708A NoticePRICE SENSITIVE18/07/18
DXB Further US patent allowed for DMX-200PRICE SENSITIVE02/07/18
DXB Investor Presentation20/06/18
DXB Change of Director's Interest Notice30/05/18
DXB Change of Director's Interest Notice29/05/18
DXB Dual Phase 2 trials launched for CKDPRICE SENSITIVE15/05/18
DXB LEAD INVESTIGATOR ENGAGED FOR NEXT STAGE OF DMX-200 TRIALS07/05/18
DXB Completion of Unmarketable Parcel Sale Facility02/05/18
DXB Dimerix to Further Bolster Management Team30/04/18
DXB Quarterly Review & Appendix 4CPRICE SENSITIVE27/04/18
DXB NDF Research updated analyst coverage13/04/18
DXB Westar Capital Retained as Corporate AdvisorsPRICE SENSITIVE12/04/18
DXB CMO Appointment and Clinical Trials UpdatePRICE SENSITIVE27/03/18
DXB Channel 7 News Segment13/03/18
DXB Unmarketable Parcel Share Sale Facility09/03/18
DXB Ceasing to be a substantial holder01/03/18
DXB Change in substantial holding28/02/18
DXB LR 3.10.5A Disclosure28/02/18
DXB Appendix 3B and Cleansing Notice28/02/18
DXB Change in substantial holding27/02/18
DXB Half Year Report and Financial StatementsPRICE SENSITIVE26/02/18
DXB Oversubscribed Placement to Raise a Further $4.5mPRICE SENSITIVE21/02/18
DXB Trading HaltPRICE SENSITIVE19/02/18
DXB Corporate Presentation05/02/18
DXB Change of Director's Interest Notice x 230/01/18
DXB Quarterly Review and Appendix 4CPRICE SENSITIVE29/01/18
DXB Appendix 3B25/01/18
DXB Results of Entitlement OfferPRICE SENSITIVE24/01/18
DXB Recorded interview with CEO and rights issue update16/01/18
DXB DMX-200 Dosage Optimisation Study Successfully CompletedPRICE SENSITIVE08/01/18
DXB Appendix 3B08/01/18
DXB Proteomics partners diagnostic test with Dimerix kidney drug14/12/17
DXB Proteomics partnership to improve treatment of CKDPRICE SENSITIVE14/12/17
DXB Dispatch of Offer Document and Entitlement and Forms13/12/17
DXB Audio interview with CEO11/12/17
DXB Reinstatement to Official QuotationPRICE SENSITIVE06/12/17
DXB Letters to Shareholders and Option Holders06/12/17
DXB Appendix 3B06/12/17
DXB Entitlement Offer BookletPRICE SENSITIVE06/12/17
DXB Cleansing Notice06/12/17
DXB Entitlement Offer to raise $5.5 millionPRICE SENSITIVE06/12/17
DXB Suspension from Official QuotationPRICE SENSITIVE05/12/17
DXB Trading HaltPRICE SENSITIVE01/12/17
DXB Dimerix Presenting at World Diabetes Congress27/11/17
DXB Change of Director's Interest Notices X 423/11/17
DXB Corporate Presentation22/11/17
DXB Appendix 3B17/11/17
DXB Appendix 3B and Cleansing Statement10/11/17
DXB Updated Equity Research Report Published08/11/17
DXB Corporate Presentation BioEurope08/11/17
DXB Baker Young Stockbroking Issues Flash Note Report06/11/17
DXB DMX-200 Phase 2a Data Presentation02/11/17
DXB Dimerix Phase 2a Subgroup Analysis ResultsPRICE SENSITIVE02/11/17
DXB Quarterly Review and Appendix 4CPRICE SENSITIVE31/10/17
DXB Securities on Issue Post Consolidation31/10/17
DXB Baker Young Stockbroking initiates coverage on Dimerix24/10/17
DXB Ethics Committee Approval for Pharmacokinetic TrialPRICE SENSITIVE24/10/17
DXB Update - Consolidation/Split - DXB19/10/17
DXB Results of Meeting19/10/17
DXB AGM Presentation19/10/17
DXB Dimerix Appoints Medical Advisory Board18/10/17
DXB Dimerix Receives $545k R&D Tax RefundPRICE SENSITIVE17/10/17
DXB Shareholder Update27/09/17
DXB Notice of Annual General Meeting - corrected13/09/17
DXB Consolidation/Split - DXB13/09/17
DXB Investor Presentation13/09/17
DXB Notice of Annual General Meeting/Proxy FormPRICE SENSITIVE13/09/17
DXB DMX-200 tablet manufacture and human study timelinePRICE SENSITIVE05/09/17
DXB Appendix 4G and Corporate Governance Statement30/08/17
DXB Appendix 3B
15/03/19
DXB Trial Update Presentation
05/03/19
DXB Half Year Report & DMX-200 Clinical Trials Update
26/02/19
DXB Half Yearly Report and Accounts
26/02/19PRICE SENSITIVE
DXB Appendix 4C and Quarterly Highlights
31/01/19PRICE SENSITIVE
DXB Appendix 3B
29/01/19
DXB Appendix 3B
14/01/19
DXB Dimerix Receives R&D Tax Cash Rebate Totalling $1.07m
20/12/18PRICE SENSITIVE
DXB Change of Director's Interest Notice
27/11/18
DXB Appendix 3B
27/11/18
DXB Dimerix Awarded $50,000 Innovation Connections Grant
26/11/18
DXB 1st Patient Dosed in DMX-200 Clinical Trial for FSGS
22/11/18PRICE SENSITIVE
DXB DXB Receives Orphan Drug Designation in EU
21/11/18PRICE SENSITIVE
DXB FIRST PATIENT DOSED IN DMX-200 CLINICAL TRIAL
19/11/18PRICE SENSITIVE
DXB Change of Address
12/11/18
DXB Results of Meeting
30/10/18
DXB AGM Presentation and CEO Address
30/10/18
DXB Appendix 4C - quarterly
29/10/18PRICE SENSITIVE
DXB AGM Dial-In Details
25/10/18
DXB Investor Update
15/10/18
DXB Appendix 3B
24/09/18
DXB Notice of Annual General Meeting/Proxy Form
21/09/18
DXB Change of Director's Interest Notice
11/09/18
DXB Annual Report to shareholders
30/08/18
DXB Appendix 4G and Corporate Governance Statement
30/08/18
DXB Preliminary Final Report
30/08/18PRICE SENSITIVE
DXB Initial Director's Interest Notice
28/08/18
DXB EXECUTIVE TEAM BOLSTERED THROUGH CEO & MD APPOINTMENT
27/08/18PRICE SENSITIVE
DXB Quarterly Review & Appendix 4C
31/07/18PRICE SENSITIVE
DXB Company Presentation
27/07/18
DXB Change of Director Interest Notices x 2
24/07/18
DXB Ethics Approval Received Appendix 3B and S.708A Notice
18/07/18PRICE SENSITIVE
DXB Further US patent allowed for DMX-200
02/07/18PRICE SENSITIVE
DXB Investor Presentation
20/06/18
DXB Change of Director's Interest Notice
30/05/18
DXB Change of Director's Interest Notice
29/05/18
DXB Dual Phase 2 trials launched for CKD
15/05/18PRICE SENSITIVE
DXB LEAD INVESTIGATOR ENGAGED FOR NEXT STAGE OF DMX-200 TRIALS
07/05/18
DXB Completion of Unmarketable Parcel Sale Facility
02/05/18
DXB Dimerix to Further Bolster Management Team
30/04/18
DXB Quarterly Review & Appendix 4C
27/04/18PRICE SENSITIVE
DXB NDF Research updated analyst coverage
13/04/18
DXB Westar Capital Retained as Corporate Advisors
12/04/18PRICE SENSITIVE
DXB CMO Appointment and Clinical Trials Update
27/03/18PRICE SENSITIVE
DXB Channel 7 News Segment
13/03/18
DXB Unmarketable Parcel Share Sale Facility
09/03/18
DXB Ceasing to be a substantial holder
01/03/18
DXB Change in substantial holding
28/02/18
DXB LR 3.10.5A Disclosure
28/02/18
DXB Appendix 3B and Cleansing Notice
28/02/18
DXB Change in substantial holding
27/02/18
DXB Half Year Report and Financial Statements
26/02/18PRICE SENSITIVE
DXB Oversubscribed Placement to Raise a Further $4.5m
21/02/18PRICE SENSITIVE
DXB Trading Halt
19/02/18PRICE SENSITIVE
DXB Corporate Presentation
05/02/18
DXB Change of Director's Interest Notice x 2
30/01/18
DXB Quarterly Review and Appendix 4C
29/01/18PRICE SENSITIVE
DXB Appendix 3B
25/01/18
DXB Results of Entitlement Offer
24/01/18PRICE SENSITIVE
DXB Recorded interview with CEO and rights issue update
16/01/18
DXB DMX-200 Dosage Optimisation Study Successfully Completed
08/01/18PRICE SENSITIVE
DXB Appendix 3B
08/01/18
DXB Proteomics partners diagnostic test with Dimerix kidney drug
14/12/17
DXB Proteomics partnership to improve treatment of CKD
14/12/17PRICE SENSITIVE
DXB Dispatch of Offer Document and Entitlement and Forms
13/12/17
DXB Audio interview with CEO
11/12/17
DXB Reinstatement to Official Quotation
06/12/17PRICE SENSITIVE
DXB Letters to Shareholders and Option Holders
06/12/17
DXB Appendix 3B
06/12/17
DXB Entitlement Offer Booklet
06/12/17PRICE SENSITIVE
DXB Cleansing Notice
06/12/17
DXB Entitlement Offer to raise $5.5 million
06/12/17PRICE SENSITIVE
DXB Suspension from Official Quotation
05/12/17PRICE SENSITIVE
DXB Trading Halt
01/12/17PRICE SENSITIVE
DXB Dimerix Presenting at World Diabetes Congress
27/11/17
DXB Change of Director's Interest Notices X 4
23/11/17
DXB Corporate Presentation
22/11/17
DXB Appendix 3B
17/11/17
DXB Appendix 3B and Cleansing Statement
10/11/17
DXB Updated Equity Research Report Published
08/11/17
DXB Corporate Presentation BioEurope
08/11/17
DXB Baker Young Stockbroking Issues Flash Note Report
06/11/17
DXB DMX-200 Phase 2a Data Presentation
02/11/17
DXB Dimerix Phase 2a Subgroup Analysis Results
02/11/17PRICE SENSITIVE
DXB Quarterly Review and Appendix 4C
31/10/17PRICE SENSITIVE
DXB Securities on Issue Post Consolidation
31/10/17
DXB Baker Young Stockbroking initiates coverage on Dimerix
24/10/17
DXB Ethics Committee Approval for Pharmacokinetic Trial
24/10/17PRICE SENSITIVE
DXB Update - Consolidation/Split - DXB
19/10/17
DXB Results of Meeting
19/10/17
DXB AGM Presentation
19/10/17
DXB Dimerix Appoints Medical Advisory Board
18/10/17
DXB Dimerix Receives $545k R&D Tax Refund
17/10/17PRICE SENSITIVE
DXB Shareholder Update
27/09/17
DXB Notice of Annual General Meeting - corrected
13/09/17
DXB Consolidation/Split - DXB
13/09/17
DXB Investor Presentation
13/09/17
DXB Notice of Annual General Meeting/Proxy Form
13/09/17PRICE SENSITIVE
DXB DMX-200 tablet manufacture and human study timeline
05/09/17PRICE SENSITIVE
DXB Appendix 4G and Corporate Governance Statement
30/08/17
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
32.5¢ 		Change
-0.010(2.99%) 		Mkt cap ! $211.6M
Open High Low Value Volume
33.5¢ 33.5¢ 30.0¢ $471.6K 1.443M

Buyers (Bids)

No. Vol. Price($)
4 23447 32.5¢
 

Sellers (Offers)

Price($) Vol. No.
33.5¢ 100000 1
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
33.0¢ 		  Change
-0.010 ( 2.94 %)
Open High Low Volume
32.5¢ 33.5¢ 30.5¢ 880183
Last updated 15.56pm 21/11/2024 ?
DXB (ASX) Chart

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.